Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT — Richard S. Finn (2024) | RDL Network
Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT
Article 2024 en
Authors
RF
Richard S. Finn
SQ
Shukui Qin
FP
Fabio Piscaglia
Abstract
1 min read
Responses were seen even in those patients with more severe disease at baseline. Tumor responses occurred early and were durable.
Masatoshi Kudo, Shukui Qin, Fabio Piscaglia, Arndt Vogel, T.R. Jeffry Evans, Jennifer J. Knox, Carlos López, Zahra Ramji, Min Ren, Kalgi Mody, Richard S. Finn
Masafumi Ikeda, Max W. Sung, Masatoshi Kudo, Masahiro Kobayashi, Ari David Baron, Richard S. Finn, Shuichi Kaneko, Andrew X. Zhu, Tomoki Kubota, Silvija Kraljevic, Kohei Ishikawa, Abby B. Siegel, Hiromitsu Kumada, Takuji Okusaka
Richard S. Finn, Masafumi Ikeda, Andrew X. Zhu, Max W. Sung, Ari David Baron, Masatoshi Kudo, Takuji Okusaka, Masahiro Kobayashi, Hiromitsu Kumada, Shuichi Kaneko, Marc Pracht, K. G Mamontov, Tim Meyer, Tomoki Kubota, Corina E. Dutcus, Kenichi Saito, Abby B. Siegel, Leonid Dubrovsky, Kalgi Mody, Josep M. Llovet
Arndt Vogel, Catherine Frenette, Max W. Sung, Bruno Daniele, Ari David Baron, Stephen L. Chan, Jean Frédéric Blanc, Toshiyuki Tamai, Min Ren, Howard J. Lim, Daniel H. Palmer, Yuko Takami, Masatoshi Kudo
Discussion(0)
No comments yet. Be the first to comment.